Navigation Links
STALLERGENES: ORALAIR Grasses: Positive Results of VO52.06 Paediatric Study
Date:11/28/2007

ANTONY, France, November 28 /PRNewswire-FirstCall/ -- The results of a study on children confirmed the efficacy of the ORALAIR(R) Grasses sublingual desensitisation product, which is due to receive German market authorisation shortly.

The phase III paediatric study, VO52.06, which was carried out on 280 patients in 5 European countries suffering from allergic rhino-conjunctivitis, fully met the main evaluation criterion by demonstrating a statistically significant reduction in symptoms, comparable to that observed in the VO34.04 adult study.

Based on this study, STALLERGENES will request the indication of the ORALAIR(R) Grasses market authorisation to be extended to children.

In addition, results of the first long term adult study (VO53) will be available by the end of the year.

STALLERGENES is confident in the commercial launch of ORALAIR(R) Grasses in Europe.

At the same time, as part of the Company's expansion in the US, the proposal for two phase III clinical studies in the US (adults and children), planned for 2009, was received favourably by the FDA and American experts. Talks with potential partners are ongoing.

All these items will be subject to an information meeting on 10 December 2007.

About Stallergenes

Stallergenes is a European biopharmaceutical company dedicated to desensitization treatments for the prevention and cure of allergy-related respiratory diseases, e.g. rhino-conjunctivitis and allergic asthma.

Pioneer and leader in sublingual desensitization treatments, Stallergenes devotes 18% of its sales to Research and Development and is today fully involved in the development of a new therapeutic family, the sublingual desensitization tablets.

STALLERGENES realised 2006 sales of EUR 126.5 million, primarily from European markets.

Stallergenes' shares are listed on Eurolist Compartment B of the Euronext Paris Stock Exchange.

ISIN code: FR0000065674, Reuters code: GEN.PA, Bloomberg code: GEN.FP

Additional information on STALLERGENES is available on our website: http://www.stallergenes.com


'/>"/>
SOURCE Stallergenes
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
3. YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION
4. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
5. MIGENIX to Present Positive Celgosivir Viral Resistance Data at International HCV Meeting
6. Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting
7. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
8. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
9. Ocera Therapeutics Announces Positive Results with AST-120 in Pouchitis
10. Hospiras Biosimilar Epoetin Retacrit(TM) Receives Positive Opinion Recommending EU Approval
11. Blood Donations in U.S. Testing Positive for Chagas Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... 2017 , ... LabKey and collaborator Just Biotherapeutics, Inc. (Just) ... LabKey Biologics . Built in collaboration with Just and designed with input from ... research teams tools for biological entity registration, assay data integration, and workflow management ...
(Date:3/28/2017)... ... March 28, 2017 , ... T3D Therapeutics, ... new orally administered treatment for Alzheimer’s disease (AD), today announced that Dr. Kathleen ... we seek to uniquely treat the metabolic dysfunctions inherent in Alzheimer’s disease and ...
(Date:3/27/2017)... ... March 27, 2017 , ... Biopsies ... small, heterogeneous samples with limited tumor content in a large background of normal ... such as the need for reliable detection of low abundance somatic mutations, particularly ...
(Date:3/27/2017)... ... March 27, 2017 , ... PMG Research is pleased to announce ... by The Conference Forum in Boston on April 3-4, 2017. The CTC conference focuses ... trial outcomes and bring them closer to the patient. Clinical Trial Collaborations also will ...
Breaking Biology Technology:
(Date:2/28/2017)... , Feb. 28, 2017   Acuant , a ... globally, announces significant enhancements to new and core technologies ... New products include mobile and desktop Acuant FRM TM ... - a real time manual review of identity ... technology provides the fastest and most accurate capture software ...
(Date:2/24/2017)... -- EyeLock LLC, a leader of iris-based identity authentication ... solution on the latest Qualcomm® Snapdragon™ 835 mobile ... Congress 2017 (February 27 – March 2, ... Stand 3E10. The Snapdragon 835 ... combination of hardware, software and biometrics technologies ...
(Date:2/14/2017)... , Feb. 14, 2017  Wake Forest Baptist ... as its new chief executive officer (CEO). Freischlag joins ... John D. McConnell , M.D., who last year ... at the Medical Center, after leading it since 2008. ... full scope of Wake Forest Baptist,s academic health system, ...
Breaking Biology News(10 mins):